PARP1 and ovarian carcinoma: Of note, this synergistic effect of talazoparib plus DHS was not limited to ovarian cancers, as similar enhancement in DSBs while EdU incorporation is simultaneously suppressed in replicating cells were also observed in MCF‐7 (breast carcinoma; Figure S48A–C, Supporting Information), IMR32 (neuroblastoma; Figure S49A–C, Supporting Information) and MIA‐PaCa‐2 (pancreatic ductal adenocarcinoma; Figure S50A–C, Supporting Information), suggesting this combination treatment may also be extended to other cancer types, where PARP inhibitor therapy is extensively pursued.